MARK2P12

Across TCGA pan-cancer cohorts, MARK2P12 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated MARK2P12 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MARK2P12 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MARK2P12 expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

LIHC, THYM, and KICH are the cancer types where MARK2P12 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.155	0.552	<.001	99	view →
THYM	OS	Tertile	III,IV	0.103	0.944	<.001	78	view →
KICH	OS	Tertile	III,IV	0.178	0.847	<.001	36	view →
LUAD	OS	Tertile	III,IV	0.211	0.668	.008	36	view →
LGG	DFS	Tertile	All	0.375	0.745	<.001	33	view →
BLCA	DFS	Tertile	All	0.491	0.645	.020	27	view →
SKCM	OS	Tertile	IV	0.179	0.727	<.001	21	view →
THCA	DFS	Tertile	All	0.739	0.924	.006	21	view →
STAD	OS	Quartile	II,III,IV	0.345	0.601	.016	18	view →
KIRC	OS	Tertile	II,III,IV	0.403	0.558	.031	12	view →
OV	OS	Tertile	IV	0.619	0.311	.007	12	view →
KIRP	OS	Tertile	All	0.291	0.729	.017	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

MARK2P12–LIHC (DFS)

Open the LIHC breakdown →